President Joe Biden (Susan Walsh/AP Images)
December 14, 2023 07:04 AM EST
Pharma
FDA+
Law

White House keeps fo­cus on low­er­ing drug prices, turns Re­gen­eron's con­tract lan­guage in­to new stan­dard

Zachary Brennan

Senior Editor

As Pres­i­dent Joe Biden strug­gles in the most re­cent 2024 gen­er­al elec­tion polls, the White House is keep­ing its fo­cus on drug prices, go­ing af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times